Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone (cas 116313-94-1), a COMT Inhibitor with Antioxidant Properties
-
Add time:08/11/2019 Source:sciencedirect.com
We attempted to characterize a spinal neuronal correlate of painful neuropathy induced by diabetes mellitus (DM). Pain behavior and response properties of spinal dorsal horn neurons were determined in rats with a streptozocin-induced DM. A catechol-O-methyltransferase inhibitor with potent antioxidant properties, nitecapone, was used in an attempt to attenuate neuropathic symptoms. Behaviorally DM induced mechanical hypersensitivity that was markedly attenuated by oral treatment with nitecapone. The antihyperalgesic effect of nitecapone was not reversed by naloxone, an opioid antagonist, or atipamezole, an α-2-adrenoceptor antagonist. Electrophysiological recordings performed in pentobarbitone-anesthetized animals revealed that the most distinct abnormality in response properties of spinal dorsal horn wide-dynamic range (WDR) neurons was the increase in their spontaneous activity observed in untreated but not in nitecapone-treated DM rats. Conditioning electrical stimulation and a lidocaine block of the rostroventromedial medulla (RVM) had a similar modulatory effect on evoked responses of spinal dorsal horn WDR neurons in all experimental groups. The response properties of spinal dorsal horn nociceptive-specific or low-threshold mechanoreceptive neurons were not markedly different between the experimental groups. The results indicate that increased spontaneous activity in spinal dorsal horn WDR neurons may be causally related to behaviorally observed mechanical hypersensitivity in DM. Attenuation of the increased spontaneous activity in WDR neurons may explain the antihyperalgesic effect by nitecapone, due to naloxone- and α-2-adrenoceptor-insensitive mechanisms. DM or nitecapone treatment did not produce significant changes in phasic or tonic descending pain regulation originating in the RVM.
We also recommend Trading Suppliers and Manufacturers of Nitecapone (cas 116313-94-1). Pls Click Website Link as below: cas 116313-94-1 suppliers
Prev:[54] Antioxidant activity of Nitecapone (cas 116313-94-1) and its analog OR-1246: Effect of structural modification on antioxidant action
Next:Entacapone (cas 116314-67-1) and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- [54] Antioxidant activity of Nitecapone (cas 116313-94-1) and its analog OR-1246: Effect of structural modification on antioxidant action08/10/2019
- Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: Effect of Nitecapone (cas 116313-94-1)08/09/2019
- Determination of a catechol-O-methyltransferase inhibitor, Nitecapone (cas 116313-94-1), in human plasma and urine by liquid chromatography08/08/2019
- Protection against alcohol-induced gastric mucosal injury by Nitecapone (cas 116313-94-1)08/07/2019
- Nitecapone (cas 116313-94-1) as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting08/06/2019
- Nitecapone (cas 116313-94-1) effect on the synthesis and secretion of gastric sulfomucin08/05/2019
- Role of ascorbate in protection by Nitecapone (cas 116313-94-1) against cardiac ischemia-reperfusion injury08/04/2019
- Antioxidant properties of Nitecapone (cas 116313-94-1) (OR-462)08/03/2019
- Nitecapone (cas 116313-94-1) reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats08/02/2019